Clinical Trials Highlighted at the AACR Annual Meeting 2015
This year, at the AACR Annual Meeting held in Philadelphia April 18 to 22, an astounding 19,300 members of...
Tag: Cancer immunotherapy
This year, at the AACR Annual Meeting held in Philadelphia April 18 to 22, an astounding 19,300 members of...
This year may indeed be the year in which a class of immunotherapeutics called PD-1 and PD-L1 inhibitors are...
Game-changing modern cancer therapies—immunotherapies and targeted therapies, among others—have been providing promising treatment outcomes in the recent years. The...
Immunotherapeutics called PD-1 inhibitors have garnered a lot of attention in the past year thanks to exciting clinical trial...
There has been a series of immunotherapy approvals since the end of last year, and following this trend, on...
The field of cancer immunotherapy broke new ground last week when the U.S. Food and Drug Administration (FDA) announced...
Big progress was made in 2014, in the form of FDA approvals for new immunotherapies, targeted therapies, and a...
With the late-breaking and clinical trial-placeholder abstract deadlines a week away, we thought it was a good time to...
Cancer immunotherapy, which entered 2014 with the accolade of Science magazine’s Breakthrough of the Year for 2013, ended the...
Check out the 10 blog posts from 2014 that attracted the most attention. They cover a lot of ground,...